Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
You may find more results for this query on our sister sites:
GenomeWeb
and
360Dx
.
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Partner Content
Virtual Molecular Tumor Board Series
Menu
Home
›
About Us
›
Our Staff
›
Allan Nixon
Allan Nixon
Director of Business Development, Premium Content
Phone Number
+1-212-651-5623
Email
[email protected]
Breaking
News
Epizyme Exploring Tazverik Combinations in Basket Trials
Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership
John Hopkins, Akoya Biosciences Ink Deal to Advance New Immunotherapy Biomarkers
Molecular Health Inks Agreement for Precision Medicine Tools With Falco Biosystems
Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs
Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use
